HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most widely used palliative
treatment for hepatocellular carcinoma (HCC) patients. While a number of studies demonstrate
poor effect of D-TACE for patients in Advanced Unresectable HCC. The investigators previous
study also revealed similar results in Advanced Unresectable HCC patients treated with
D-TACE. Recently, the investigators previous study demonstrated that, compared with D-TACE,
hepatic arterial infusion chemotherapy (HAIC) may improve tumor response in Advanced
Unresectable HCC. Thus, the investigators carried out this prospective nonrandomized control
to demonstrate the superiority of HAIC-based combination therapy over D-TACE-based
combination therapy.